Travere Therapeutics Relocates Principal Executive Offices

TL;DR

Travere Therapeutics moved its HQ to San Diego, CA effective 9/10/25.

AI Summary

On September 10, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130. This move is effective as of September 10, 2025.

Why It Matters

A change in principal executive offices can signal operational shifts or growth for a company. Investors should monitor if this move is associated with other strategic changes.

Risk Assessment

Risk Level: low — This filing reports a change of address for the company's principal executive offices, which is a routine administrative event.

Key Players & Entities

• Travere Therapeutics, Inc. (company) — Registrant
• 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (location) — New Principal Executive Offices
• September 10, 2025 (date) — Effective Date of Address Change

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share TVTX The Nasdaq Global Marke

Filing Documents

• tvtx-20250910.htm (8-K) — 39KB
• 0001438533-25-000049.txt ( ) — 158KB
• tvtx-20250910.xsd (EX-101.SCH) — 2KB
• tvtx-20250910_lab.xml (EX-101.LAB) — 22KB
• tvtx-20250910_pre.xml (EX-101.PRE) — 13KB
• tvtx-20250910_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On September 10, 2025, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that following further review of the supplemental New Drug Application ("sNDA") for FILSPARI (sparsentan) in focal segmental glomerulosclerosis ("FSGS"), an advisory committee is no longer needed. The sNDA remains under review by the FDA with a Prescription Drug User Fee Act ("PDUFA") target action date of January 13, 2026. If approved, FILSPARI would be the first medication indicated for FSGS, a rare and serious kidney disorder driven by proteinuria that leads to progressive kidney function loss and kidney failure. FILSPARI is an oral, non-immunosuppressive potential therapy that targets podocyte injury, a key driver of FSGS progression. The sNDA is supported by two of the largest and most rigorous head-to-head interventional studies conducted to date in FSGS, the Phase 3 DUPLEX Study and the Phase 2 DUET Study. In these studies, FILSPARI demonstrated rapid, superior and sustained reductions in proteinuria when compared with maximum labeled dose irbesartan across adult and pediatric patients. As published in the New England Journal of Medicine , DUPLEX showed statistically significant and clinically meaningful proteinuria remission at 36 weeks that was durable through 2 years. Patients who achieved partial or complete proteinuria remission in the DUPLEX Study, irrespective of the treatment arm, had a 67% to 77% lower risk of kidney failure, respectively, with the treatment effect of FILSPARI strengthened at more stringent thresholds down to complete remission. The results from these studies are in alignment with the findings of the independent PARASOL workgroup that support the importance of proteinuria in FSGS. FILSPARI was well-tolerated in the studies with a safety profile consistent across trials and comparable to irbesartan. FILSPARI is fully approved by the FDA and EMA to slow ki

Forward-Looking Statements

Forward-Looking Statements This report contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words "on-track," "positioned," "look forward to," "will," "would," "may," "might," "believes," "anticipates," "plans," "expects," "intends," "potential," or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements relating to the clinical studies and data described herein; statements and expectations regarding the FDA's ongoing review of the sNDA for FILSPARI in FSGS, and the timing and outcome thereof; statements regarding the potential for FILSPARI to be the first medication indicated for FSGS; and statements related to the estimated sizes of patient populations. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to the Company's sNDA for FILSPARI in FSGS, including the timing and outcome thereof. There is no guarantee that the FDA will grant approval of FILSPARI for FSGS on the anticipated timeline, or at all. The Company also faces risks and uncertainties related to its business and finances in general, the success of its commercial products, risks and uncertainties associated with its preclinical and clinical stage pipeline, risks and uncertainties associated with the regulatory review and approval process, risks and uncertainties associated with enrollment

View Full Filing

View this 8-K filing on SEC EDGAR